TL;DR
Researchers have developed a novel structure-based approach to discover potent inhibitors of LAT1, a crucial transporter for cancer cell growth. By combining homology modeling, molecular dynamics, and virtual screening, they identified 13 new LAT1 inhibitors, including two with sub-micromolar IC50 values, offering promising avenues for cancer therapy.
What Problem Does This Paper Address?
Cancer cells rely heavily on essential amino acids for their rapid growth and proliferation. The Large Neutral Amino Acid Transporter 1 (LAT1) plays a critical role in facilitating the uptake of these vital building blocks into cancer cells. Consequently, LAT1 has emerged as a promising therapeutic target for cancer treatment. However, despite its importance, only a few potent LAT1 inhibitors were known, necessitating the discovery of new, chemically diverse, and effective compounds. The challenge lies in identifying molecules that can specifically and potently inhibit LAT1's function.
Methods
The study employed a multi-faceted, structure-based drug discovery strategy:
- Homology Modeling: A 3D model of human LAT1 was constructed using the crystal structures of its prokaryotic homologs (AdiC and ApcT). This provided a structural basis for understanding the transporter's architecture and binding site.
- Molecular Docking: Nitrogen mustard (NM) derivatives were docked into the homology model to identify a common binding mode (CBM). This helped explain existing structure-activity relationships (SAR) for these compounds.
- Molecular Dynamics (MD) Simulations: The validated binding hypotheses from docking were further refined using MD simulations. This allowed for the extraction of dynamic pharmacophores, capturing the real-time interactions between ligands and the transporter.
- Virtual Screening: A massive library of approximately 1.1 million molecules was screened against the dynamic pharmacophores. This was followed by a docking step to prioritize potential inhibitors.
- Experimental Testing: The top-ranked hits from the virtual screening were experimentally tested for their ability to inhibit LAT1 activity.
Datasets
- Protein Structures: Crystal structures of the arginine/agmatine antiporter AdiC (PDB ID: 3L1L) and the APC transporter ApcT (PDB ID: 3GIA) were used as templates for homology modeling.
- Ligand Libraries:
- Five conformationally restricted analogs of phenylalanine (8-12) were used for initial docking and CBM elucidation.
- A large library of ~1.1 million commercially available molecules from DrugBank, Chembridge, Enamine, and Sigma-Aldrich was used for virtual screening.
- Known LAT1 Ligands: A set of 97 known LAT1 ligands and 5300 decoys were used for validating the pharmacophore models.
Key Insights and Ideas
- Dynamic Pharmacophores are Crucial: Relying solely on static models can be limiting. Capturing the dynamic nature of protein-ligand interactions through MD simulations and dynamic pharmacophores significantly improved the prediction of potent inhibitors.
- Structure-Based Design is Effective for Transporters: Even with limited sequence identity to known structures, homology modeling of prokaryotic homologs can provide a reliable template for designing inhibitors for complex membrane transporters like LAT1.
- Hydrophobic Interactions Drive Potency: While the amino acid moiety is essential for initial recognition, the hydrophobic interactions within the binding pocket, particularly in the "hydrophobic sub-pocket" (HSP), play a significant role in determining the potency of LAT1 inhibitors.
- Chemical Diversity Achieved: The structure-based approach successfully identified inhibitors that were chemically unrelated to known LAT1 ligands, suggesting a novel mechanism of action or binding.
Key Results
- A homology model of human LAT1 was successfully constructed and validated.
- A common binding mode (CBM) for NM derivatives was proposed, explaining their SAR.
- Dynamic pharmacophores were generated and used to screen a library of ~1.1 million molecules.
- Out of 30 compounds experimentally tested, 13 showed LAT1 inhibitory activity.
- The most potent inhibitors, compounds 36 and 42, demonstrated complete inhibition of LAT1 at 100 µM.
- Dose-response analysis revealed IC50 values of 0.64 ± 0.12 µM for compound 36 and 1.48 ± 0.27 µM for compound 42, significantly more potent than the reference compound BCH.
Limitations and Future Work
- In Vitro vs. In Vivo: The study used proteoliposomes for experimental testing, which lack the complexity of a cellular environment. Future work should involve testing these inhibitors in cellular models and in vivo to assess their efficacy and pharmacokinetic properties.
- Mechanism of Inhibition: While potent inhibitors were identified, the precise molecular mechanism of inhibition for all newly discovered compounds requires further investigation.
- Drug-like Properties: While the identified compounds show promise, further optimization may be needed to improve their drug-like properties (e.g., solubility, metabolic stability) for clinical development.
- Broader Applicability: The authors suggest that the validated structure-based methodology could be extended to discover inhibitors for other essential biological transporters.
Summary updated